Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Neovascular Age-related Macular Degeneration(nAMD)”

156 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 156 results

Not applicableEnded earlyNCT05112835
What this trial is testing

Brolucizumab Treatment Experience Study of Patients With nAMD in UK Routine Clinical Practice

Who this might be right for
Neovascular Age-related Macular Degeneration
Novartis Pharmaceuticals 302
Testing effectiveness (Phase 2)Temporarily pausedNCT05961007
What this trial is testing

Evaluation of IBI302 Injection in nAMD or DME

Who this might be right for
Neovascular Age-related Macular DegenerationDiabetic Macular Edema
Innovent Biologics (Suzhou) Co. Ltd. 234
Large-scale testing (Phase 3)Looking for participantsNCT07007065
What this trial is testing

Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)

Who this might be right for
Neovascular Age-related Macular Degeneration
AbbVie 561
Not applicableActive Not RecruitingNCT04645212
What this trial is testing

Long-term Study of ADVM-022 in Neovascular (Wet) AMD [OPTIC-EXT]

Who this might be right for
Wet Age-related Macular DegenerationNeovascular Age-related Macular Degeneration
Adverum Biotechnologies, Inc. 23
Not applicableStudy completedNCT05324150
What this trial is testing

M Charts Versus Amsler Test in Evaluating Metamorphopsia in nAMD

Who this might be right for
Macular Degeneration, WetMetamorphopsia
Ospedale Santa Croce-Carle Cuneo 57
Not applicableLooking for participantsNCT07640997
What this trial is testing

Real-world Study of Aflibercept 8 mg in nAMD

Who this might be right for
Neovascular Age-Related Macular Degeneration (nAMD)
Peking University People's Hospital 300
Early research (Phase 1)Active Not RecruitingNCT06198413
What this trial is testing

LX102 in Patients With Neovascular Age-Related Macular Degeneration (nAMD)

Who this might be right for
Neovascular Age-Related Macular Degeneration
Innostellar Biotherapeutics Co.,Ltd 12
Early research (Phase 1)Not Yet RecruitingNCT07817615
What this trial is testing

A Phase I Study of GenSci148 Intravitreal Injection for Neovascular Age-related Macular Degeneration, Diabetic Macular Edema and Retinal Vein Occlusion

Who this might be right for
Neovascular Age-related Macular Degeneration (nAMD)Diabetic Macular Edema (DME)Retinal Vein Occlusion (RVO)
Changchun GeneScience Pharmaceutical Co., Ltd. 60
Early research (Phase 1)Study completedNCT05345769
What this trial is testing

Safety and Efficacy of AM712 in Patients with NAMD

Who this might be right for
Neovascular Age-related Macular Degeneration
AffaMed Therapeutics Limited 21
Not applicableEnded earlyNCT04935411
What this trial is testing

Russian Registry of Patients With nAMD

Who this might be right for
Neovascular Age-Related Macular Degeneration
Novartis Pharmaceuticals 2,665
Early research (Phase 1)Study completedNCT04635800
What this trial is testing

Evaluate the Safety, Tolerability and Pharmacokinetics of IVT MHU650 in Macular Edema Patients

Who this might be right for
Macular EdemaDiabetic Macular EdemaNeovascular Age-related Macular Degeneration+1 more
Novartis Pharmaceuticals 21
Large-scale testing (Phase 3)Study completedNCT04423718
What this trial is testing

Study of the Effects of High Dose Aflibercept Injected Into the Eye of Patients With an Age-related Disorder That Causes Loss of Vision Due to Growth of Abnormal Blood Vessels at the Back of the Eye

Who this might be right for
Neovascular Age-Related Macular Degeneration
Bayer 1,011
Post-approval studies (Phase 4)Looking for participantsNCT05093374
What this trial is testing

Treatment of Neovascular AMD: Artificial Intelligence in Real-world Setting

Who this might be right for
Exudative Macular Degeneration
Medical University of Vienna 290
Large-scale testing (Phase 3)Not Yet RecruitingNCT07489586
What this trial is testing

A Clinical Study of QL1207H Injection Versus Aflibercept for Neovascular Age-related Macular Degeneration

Who this might be right for
Neovascular Age-Related Macular Degeneration (nAMD)
Qilu Pharmaceutical Co., Ltd. 356
Not applicableStudy completedNCT04847895
What this trial is testing

Observation of Treatment Patterns With Lucentis® in Real-life Conditions in All Approved Indications

Who this might be right for
Neovascular (Wet) Age-related Macular Degeneration
Novartis Pharmaceuticals 5,500
Large-scale testing (Phase 3)Looking for participantsNCT07614776
What this trial is testing

Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration

Who this might be right for
Neovascular Age-related Macular DegenerationnAMD
Amgen 304
Large-scale testing (Phase 3)Active Not RecruitingNCT05461339
What this trial is testing

TAB014 Compared to Lucentis® in Patients with Neovascular Age-related Macular Degeneration

Who this might be right for
Neovascular Age-related Macular Degeneration
BioDlink Biopharm Co., Ltd. 488
Not applicableUnknownNCT03893474
What this trial is testing

Quality-Assured Follow-up of Quiescent Neovascular Age -Related maculaR dEgeneration by Non-medical Practitioners

Who this might be right for
AMD
Moorfields Eye Hospital NHS Foundation Trust 742
Large-scale testing (Phase 3)Study completedNCT01948830
What this trial is testing

Randomized Study for Efficacy and Safety of Ranibizumab 0.5mg in Treat-extend and Monthly Regimens in Patients With nAMD

Who this might be right for
Age-related Macular DegenerationChoroidal Neovascularization
Novartis Pharmaceuticals 650
Not applicableActive Not RecruitingNCT06929143
What this trial is testing

Learn More About the Use of Aflibercept in Routine Medical Practice in Japanese Participants With Neovascular Age-related Macular Degeneration and Diabetic Macular Edema

Who this might be right for
Neovascular Age-related Macular Degeneration (nAMD)Diabetic Macular Edema (DME)
Bayer 3,000
Next Page